| | 144598-75-4 Basic information More.. |
| Product Name: | Paliperidone | | Synonyms: | Paliperidone (Invega);3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-9-hydroxy-2-Methyl-;Risperidone EP IMpurity C;Paliperidone
9-Hydroxyrisperidone;9-Hydroxyrisperidone solution;Racemic Paliperidone;4h-pyrido(2,1-a)pyrimidin-4-one,6,7,8,9-tetrahydro-3-(2-(4-(6-fluro-1,2-benzis;oxazol-3-yl)-1-piperidinyl)ethyl)-9-hydroxy-2-methyl- | | CAS: | 144598-75-4 | | MF: | C23H27FN4O3 | | MW: | 426.48 | | EINECS: | 620-493-1 | | Mol File: | 144598-75-4.mol |  |
Use
Paliperidone, (±)-3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one(Invega), is essentially insoluble in water and is available asextended-release tablets. Paliperidone is delivered at a constantrate using an osmotic drug release device (OsmoticRelease Oral Systems [OROS]). The absolute bioavailabilityof paliperidone is 28%, and studies in healthy subjects on ahigh-fat, high-calorie meal showed an increase in AUC.Paliperidone is 74% bound to plasma proteins. After a single,1-mg dose of C-paliperidone, 59% of the dose was excretedin the urine as unchanged drug, and 32% of the dose was recoveredas metabolites. Most of the drug (80%) is excreted bythe kidneys. Paliperidone is metabolized by dealkylation, hydroxylation,dehydrogenation, and scission of the benzoxazolering. None of these metabolic pathways account for morethan 10% of the dose. The terminal elimination half-life ofpaliperidone is 23 hours.
- Paliperidone
-
- US $0.00-0.00 / Kg/Bag
- 2024-05-27
- CAS:144598-75-4
- Min. Order: 1Kg/Bag
- Purity: 0.99
- Supply Ability: 20 tons
- Paliperidone
-
- US $0.00 / kg
- 2024-05-16
- CAS:144598-75-4
- Min. Order: 1kg
- Purity: 99%
- Supply Ability: 10000kg
- Paliperidone
-
- US $65.00-650.00 / kg
- 2024-05-10
- CAS:144598-75-4
- Min. Order: 10kg
- Purity: 0.99
- Supply Ability: 20tons
|
|
144598-75-4
Recommend Suppliers |
|